Free Cash Flow

A modest SEK 1.5 million order may not turn heads, but for Cell Impact, it's a critical validation that could unlock mass production in the booming Asian FCEV market.

With its 2026 Investor Day nearing, PHINIA aims to prove its dual-path strategy is the key to powering a diverse, carbon-conscious industrial future.

Led by a controversial figure, AlphaTON Capital pitches a bold Web3 vision in Abu Dhabi, but its grand ambitions clash with stark financial realities.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

TransAlta is converting a massive coal plant to natural gas, a pragmatic yet controversial move in the push for a cleaner, reliable energy future.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

Insiders at the newly independent Magnum Ice Cream Company show major confidence with multi-million-euro share buys following its spin-off from Unilever.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

SRN Advisors is consolidating its dividend ETFs, shifting from a defensive strategy to pure growth and highlighting a major consolidation trend in finance.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

Beyond the press release: Why Terreno's 107,000 sq. ft. deal with the Secret Service is a major indicator for the industrial real estate market.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

Osisko Development is betting big on BC's historic Cariboo region, launching a massive drilling program to uncover new gold and expand its flagship project.

Antero Resources executes a complex asset swap, doubling down on the Marcellus Shale. We break down the financial engineering behind the multi-billion dollar deal.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.